


RSC Drug Discovery

Edited by Jeremy I Levin and Stefan Laufer

Anti-Inflammatory Drug Discovery



RSC Publishing

Anti-Inflammatory Drug Discovery

Edited by

Jeremy I Levin

Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA

Stefan Laufer

Institute of Pharmacy, Tuebingen, Germany



RSC Publishing

RSC Drug Discovery Series No. 26

ISBN: 978-1-84973-413-4

ISSN: 2041-3203

A catalogue record for this book is available from the British Library

© The Royal Society of Chemistry 2012

All rights reserved

Apart from fair dealing for the purposes of research for non-commercial purposes or for private study, criticism or review, as permitted under the Copyright, Designs and Patents Act 1988 and the Copyright and Related Rights Regulations 2003, this publication may not be reproduced, stored or transmitted, in any form or by any means, without the prior permission in writing of The Royal Society of Chemistry or the copyright owner, or in the case of reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK, or in accordance with the terms of the licences issued by the appropriate Reproduction Rights Organization outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to The Royal Society of Chemistry at the address printed on this page.

The RSC is not responsible for individual opinions expressed in this work.

Published by The Royal Society of Chemistry,
Thomas Graham House, Science Park, Milton Road,
Cambridge CB4 0WF, UK

Registered Charity Number 207890

For further information see our web site at www.rsc.org

Printed in the United Kingdom by Henry Ling Limited, at the Dorset Press, Dorchester,
DT1 1HD

Anti-Inflammatory Drug Discovery

RSC Drug Discovery Series

Editor-in-Chief:

Professor David Thurston, *London School of Pharmacy, UK*

Series Editors:

Dr David Fox, *Pfizer Global Research and Development, Sandwich, UK*

Professor Salvatore Guccione, *University of Catania, Italy*

Professor Ana Martinez, *Instituto de Química Medica-CSIC, Spain*

Professor David Rotella, *Montclair State University, USA*

Advisor to the Board:

Professor Robin Ganellin, *University College London, UK*

Titles in the Series:

- | | |
|---|---|
| 1: Metabolism, Pharmacokinetics and Toxicity of Functional Groups | 14: Neglected Diseases and Drug Discovery |
| 2: Emerging Drugs and Targets for Alzheimer's Disease; Volume 1 | 15: Biomedical Imaging |
| 3: Emerging Drugs and Targets for Alzheimer's Disease; Volume 2 | 16: Pharmaceutical Salts and Cocrystals |
| 4: Accounts in Drug Discovery | 17: Polyamine Drug Discovery |
| 5: New Frontiers in Chemical Biology | 18: Proteinases as Drug Targets |
| 6: Animal Models for Neurodegenerative Disease | 19: Kinase Drug Discovery |
| 7: Neurodegeneration | 20: Drug Design Strategies: Computational Techniques and Applications |
| 8: G Protein-Coupled Receptors | 21: Designing Multi-Target Drugs |
| 9: Pharmaceutical Process Development | 22: Nanostructured Biomaterials for Overcoming Biological Barriers |
| 10: Extracellular and Intracellular Signaling | 23: Physico-Chemical and Computational Approaches to Drug Discovery |
| 11: New Synthetic Technologies in Medicinal Chemistry | 24: Biomarkers for Traumatic Brain Injury |
| 12: New Horizons in Predictive Toxicology | 25: Drug Discovery from Natural Products |
| 13: Drug Design Strategies: Quantitative Approaches | 26: Anti-Inflammatory Drug Discovery |

How to obtain future titles on publication:

A standing order plan is available for this series. A standing order will bring delivery of each new volume immediately on publication.

For further information please contact:

Book Sales Department, Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge, CB4 0WF, UK

Telephone: +44 (0)1223 420066, Fax: +44 (0)1223 420247,

Email: booksales@rsc.org

Visit our website at <http://www.rsc.org/Shop/Books/>

Preface

Driven by the need for new orally active anti-inflammatory medicines, intensive research is ongoing in both industry and academia on a diverse set of biological pathways and targets with the goal of delivering therapeutics to improve the lives of patients with conditions such as asthma, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, psoriasis, allergic diseases, and pain. It was the goal of this volume to bring together respected scientists who have been directly involved in these drug discovery efforts to present the rationale for prosecuting specific targets, a current review of the medicinal chemistry strategies that have been used, and the outcome of those efforts. For some of these targets drugs with exciting potential have been delivered to clinical trials, while others have encountered unexpected roadblocks, and both of those outcomes provide important lessons for today's drug hunters. It is our hope that the stories presented herein will serve as a valuable resource for anyone interested in the discovery of new anti-inflammatory drugs.

In addition, we would like to express our great appreciation to all of the chapter authors for delivering clear, comprehensive reviews that will inform and enlighten readers on the state of the art in their respective areas of research. We would also like to express our appreciation to Professor David Rotella (Montclair State University), and Gwen Jones and Amaya Camara at RSC Publishing for their help, support and patience in the course of putting together this book.

Jeremy I. Levin, Ph.D.
Stefan Laufer, Ph.D.

Contents

Introduction	1
Section 1: Arachidonic Acid Cascade	
Chapter 1 Microsomal Prostaglandin E₂ Synthase-1	7
<i>Andreas Koeberle and Oliver Werz</i>	
1.1 Function of PGE ₂ as Bioactive Mediator	8
1.2 PGE ₂ Biosynthesis by mPGES-1	8
1.3 Structure and Biochemical Properties of mPGES-1	9
1.4 Regulation of mPGES-1 Expression	9
1.5 Redirection of the mPGES-1 Substrate PGH ₂ Due to the Action of mPGES-1 Inhibitors	10
1.6 Determination of mPGES-1 Activity	10
1.7 mPGES-1 in Disease and Homeostasis – Results from KO Studies	11
1.7.1 Inflammation, Fever and Pain	11
1.7.2 Neurological Diseases	11
1.7.3 Cancer	12
1.7.4 Renal and Cardiovascular System	12
1.8 Direct Inhibitors of mPGES-1	12
1.8.1 MK886 Derivatives	13
1.8.2 Phenanthreneimidazoles and Related Compounds	14
1.8.3 Others	16
1.9 Dual Inhibitors of mPGES-1 and 5-LO	17
1.9.1 MK-886 and Derivatives	17
1.9.2 Pirinixic Acid Derivatives	18
1.9.3 Acylphloroglucinols	20
1.9.4 Others	20

1.10	Selective Suppressors of mPGES-1 Expression	21
1.11	Conclusion	23
	References	23
Chapter 2	Inhibitors of Cytosolic Phospholipase A₂α as Anti-inflammatory Drugs	35
	<i>Matthias Lehr</i>	
2.1	Classification of the Phospholipase A ₂ Enzymes	35
2.2	Properties and Function of Cytosolic Phospholipase A ₂ α	37
2.3	Assessment of cPLA ₂ α Inhibitors	38
2.4	Inhibitors of cPLA ₂ α	39
2.4.1	General	39
2.4.2	Trifluoromethyl Ketones and Methyl Fluorophosphonates	39
2.4.3	α,β -Dioxoesters and α -Ketoamides	41
2.4.4	Benzhydrylindoles	41
2.4.5	Thiazolidinediones	45
2.4.6	(Aryloxy)propan-2-ones	46
2.4.7	Aryl Thiazolidinones	50
2.5	Conclusions	51
	References	52
Chapter 3	Leukotriene A₄ Hydrolase: Biology, Inhibitors and Clinical Applications	58
	<i>Cheryl A. Grice, Anne M. Fourie and Alice Lee-Dutra</i>	
3.1	Background: Eicosanoids and Leukotrienes	58
3.2	Leukotriene A ₄ Hydrolase	61
3.3	LTA ₄ H – Pre-clinical and Human Genetic Rationale	62
3.3.1	Respiratory Disease	62
3.3.2	Gastrointestinal Disease	64
3.3.3	Inflammatory Arthritis	65
3.3.4	Cardiovascular Disease	66
3.3.5	Cancer	67
3.4	Small-molecule Approaches Targeting LTA ₄ H	68
3.4.1	X-ray Crystallography	69
3.4.2	G. D. Searle & Co.	70
3.4.3	Janssen Pharmaceutica NV	74
3.4.4	deCODE Genetics	81
3.4.5	Schering AG	84
3.4.6	Santen Pharmaceutical Co., Ltd	88
3.5	Clinical Evaluation of LTB ₄ Modulators	89

3.6 Summary	90
Acknowledgements	91
References	91
Chapter 4 CRTH2 Antagonists	104
<i>L. Nathan Tumey</i>	
4.1 Role of PGD2 in Inflammation and Asthma	104
4.2 Receptors for PGD2: DP and CRTH2	105
4.3 Pharmacology of CRTH2	107
4.3.1 Role of CRTH2 in Animal Disease Models	107
4.3.2 Role of CRTH2 in Human Disease	109
4.4 CRTH2 Antagonists	109
4.4.1 Tricyclic Ramatroban Antagonists	110
4.4.2 Indole Acetic Acids and Related Antagonists	112
4.4.3 Phenoxyacetic Acids, Phenyl Acetic Acids and Related Antagonists	115
4.4.4 Tetrahydroquinoline CRTH2 Antagonists	119
4.4.5 Dual CRTH2/DP Antagonists	120
4.5 Activity of CRTH2 Antagonists in Animal Efficacy Studies	121
4.6 CRTH2 Biomarkers for Clinical Development	125
4.7 CRTH2 Antagonists in Clinical Development	125
4.8 Summary	127
References	127
Section 2: Kinases	
Chapter 5 Dual Inhibition of Phosphodiesterase-4 and p38 MAP Kinase: A Strategy for Treatment of Chronic Inflammatory Diseases	137
<i>Wolfgang Albrecht and Stefan Laufer</i>	
5.1 Introduction	137
5.2 p38 MAPK	138
5.3 Binding Modes of p38 MAPK Inhibitors	141
5.4 Clinical Development of p38 MAPK Inhibitors	144
5.5 Evidences for p38 MAPK as Key Enzyme in Chronic Inflammation	146
5.6 New Indications for p38 MAPK Inhibitors	149
5.7 Therapeutic Potential of Drug Combinations with p38 MAPK Inhibitors	149
5.8 Discovery and Development of PDE4 Inhibitors	150
5.9 Dual Inhibitors of p38 MAPK and PDE4	152
5.10 Conclusion	153
References	153

Chapter 6	MAPKAP Kinase 2 (MK2) as a Target for Anti-inflammatory Drug Discovery	158
	<i>Jeremy J. Edmunds and Robert V. Talanian</i>	
6.1	Introduction	158
6.2	Oral Anti-cytokine Target Identification	159
6.2.1	p38 MAPK Signal Transduction Pathway	159
6.2.2	MK2 as an Oral Anti-inflammatory Drug Discovery Target	160
6.2.3	Mechanism of Cytokine Regulation by MK2	161
6.2.4	Functions of MK2 Beyond Cytokine Regulation	162
6.3	Medicinal Chemistry	163
6.4	Challenges in Translating MK2 Inhibition to Favourable <i>in-vivo</i> Effects	172
6.5	Summary	174
	Acknowledgements	174
	References	174
Chapter 7	Syk Kinase Inhibitors	181
	<i>Neelu Kaila, Mark S. Ryan, Atli Thorarensen and Eddine Saiah</i>	
7.1	Introduction	181
7.2	The Role of Syk in Inflammation	182
7.3	Structural Features of Syk	186
7.4	Known Chemotypes of Syk Inhibitors	186
7.4.1	Aminopyrimidines	189
7.4.2	Bicyclic 6/5 Cores	193
7.4.3	Bicyclic 6/6 Cores	198
7.4.4	Monocyclic Cores	200
7.5	Clinical Development of Syk Inhibitors	201
7.6	Summary	204
	References	204
Chapter 8	Janus Kinases – Just Another Kinase or a Paradigm Shift for the Treatment of Autoimmune Disease?	211
	<i>Michael Skynner, Phil Jeffrey, Michael Binks and Michael Woodrow</i>	
8.1	Kinase Drug Discovery	211
8.2	Janus Kinases (JAKs)	212
8.2.1	Identification and Structure of JAK Family Proteins	212
8.2.2	Signalling Mechanisms of the JAKs	217

8.2.3	Feedback Inhibition of JAKs by SOCS Proteins	217
8.2.4	JAK Cytokine Signalling	218
8.2.5	Interrogating JAK Function through Loss of Function Studies	219
8.2.6	JAK Proteins and STAT Responses	220
8.3	Mutation of JAK Proteins – Gain of Function Studies	221
8.3.1	JAK2 Gain of Function	221
8.3.2	JAK1 and JAK3 Gain of Function	222
8.4	JAK Inhibitors for Immune Mediated Disease	222
8.4.1	Introduction	222
8.4.2	JAK Drug Discovery	223
8.5	JAK Inhibitor Chemistry	223
8.5.1	Pan JAK Inhibitors	223
8.5.2	JAK3 Selective Molecules	229
8.5.3	JAK2 Selective Molecules	229
8.6	Clinical Studies with JAK Inhibitors	232
8.6.1	Tofacitinib (CP-690,550)	232
8.6.2	INCB028050 and INCB018424 (ruxolitonib) for Immune Mediated Disease	239
8.6.3	Vertex VX-509	241
8.6.4	Other JAK Inhibitors in Development	242
8.7	Conclusions and Future Perspectives	242
	References	242

Chapter 9 IKK β as a Therapeutic Intervention Point for Diseases Related to Inflammation **255**

Erick R. R. Young

9.1	Introduction	255
9.2	Target Validation	257
9.3	IKK β Therapeutic Target Considerations	258
9.3.1	Safety	258
9.3.2	NF- κ B Pathway Complexities	259
9.3.3	Isoform Selectivity	259
9.3.4	Broader Kinase Selectivity	260
9.4	Chemical Matter	260
9.4.1	Aminopyrimidines	261
9.4.2	Thiophenecarboxamides	264
9.4.3	2-Hydroxyphenylpyridines	269
9.4.4	Indole Carboxamides	272
9.4.5	Pyrazole Carboxamides	274
9.4.6	β -Carbolines	276
9.4.7	Imidazo Pyridines	277
9.4.8	Imidazo Pyridazines	280
9.5	Clinical Information	281

9.6 Future Outlook	285
Acknowledgement	285
References	285

Chapter 10 Bruton's Tyrosine Kinase (Btk) 297

Mark E. Schnute, Adrian Huang and Eddine Saiah

10.1 Introduction	297
10.2 Btk Biochemistry	299
10.3 Biological Function of Btk	299
10.3.1 Role in B-cell Development and Function	299
10.3.2 Role in Myeloid and Other Cells	302
10.4 Btk as an Anti-inflammatory Target	303
10.5 Structural Biology	304
10.6 Small-molecule Approaches to Btk Inhibition	308
10.6.1 Non-covalent, Reversible Inhibitor Strategies	309
10.6.2 Covalent Inhibitor Strategies	313
10.7 Clinical Experience with Btk Inhibitors	320
10.8 Conclusions	321
Acknowledgement	322
References	322

Section 3: GPCRs

Chapter 11 CCR1 329

J. Robert Merritt and Annette Gilchrist

11.1 Introduction	329
11.1.1 What is CCR1?	329
11.1.2 CCR1 Involvement in Cells	330
11.1.3 CCR1 Involvement in Inflammatory Diseases	331
11.1.4 CCR1 Involvement in Cancer	331
11.1.5 CCR1 Inhibitors	333
11.2 CCR1 Inhibitors in Human Trials	333
11.2.1 Berlex	333
11.2.2 Pfizer	334
11.2.3 Millennium	336
11.2.4 AstraZeneca	336
11.2.5 ChemoCentryx	337
11.3 Pre-clinical CCR1 Inhibitors	338
11.3.1 Pharmacopeia/Ligand	338
11.3.2 Novartis	339
11.3.3 Banyu and Merck	340
11.3.4 Bristol-Myers Squibb	341
11.3.5 Boehringer Ingelheim	341

11.4	Strategies to Improve CCR1 Compounds	342
11.4.1	Increase Receptor Coverage	342
11.4.2	Address Chemokine Promiscuity	342
11.4.3	Interrogate Signalling Using a Context-Dependent Approach	343
11.5	Conclusion	343
	References	344

Chapter 12 CCR2 Antagonists for the Treatment of Diseases

Associated with Inflammation 350

Cuifen Hou and Zhihua Sui

12.1	Introduction	350
12.2	Biology of CCR2	351
12.2.1	Chemokines	351
12.2.2	Monocyte Chemoattractant Protein-1 (MCP-1)	352
12.2.3	CC-Chemokine Receptor 2 (CCR2)	352
12.2.4	CCR2 Signal Transduction Pathways	353
12.2.5	Roles of CCR2 and Its Ligands in Diseases	354
12.3	Medicinal Chemistry of CCR2 Antagonists	361
12.3.1	CCR2 Antagonist Pharmacophore	362
12.3.2	Pyrrolidines	363
12.3.3	Piperidines	366
12.3.4	Azetidines	368
12.3.5	Cyclopentylamines	370
12.3.6	Cyclohexylamines	372
12.3.7	Quaternary Ammonium	374
12.3.8	Sulfonamides	374
12.3.9	Other Structures	376
12.4	Issues and Challenges	376
12.4.1	Pre-clinical Challenges	376
12.4.2	Clinical Challenges	377
12.5	Conclusion	378
	Acknowledgement	379
	References	379

Chapter 13 Recent Advances in Selective CB₂ Agonists for the Treatment of Pain

391

E. J. Gilbert and C. A. Lunn

13.1	Introduction	391
13.2	Finding Cannabinoid CB ₂ Receptors in the CNS	392

13.3	Target Biology for Cannabinoid CB ₂ Receptor Agonists	394
13.3.1	Cannabinoid CB ₂ Receptor Involvement in Pain	394
13.4	CB ₂ Agonist Chemotypes	396
13.4.1	Acyclic Cores	397
13.4.2	Monocyclic Cores	397
13.4.3	Bicyclic Cores	401
13.4.4	Tricyclic Cores	406
13.4.5	Biaryl Cores	406
13.4.6	Triaryl Cores	407
13.5	Clinical Status	407
	References	409

Section 4: Sphingolipids

Chapter 14 S1P Receptor Agonists 417

Craig A. Miller

14.1	S1P Biology and Relevance to the Pathological Features of Multiple Sclerosis	417
14.1.1	S1P Biosynthesis, Receptor Expression and Function	417
14.1.2	Pathological Features of Multiple Sclerosis	419
14.2	Discovery and Development of Fingolimod (FTY720/Gilenya [®] ; Novartis)	420
14.2.1	Discovery of Fingolimod and S1P Receptor Binding Mode	420
14.2.2	<i>In-vitro</i> and <i>in-vivo</i> Pharmacology of Fingolimod	421
14.2.3	Clinical Efficacy of Fingolimod	423
14.3	Medicinal Chemistry Approaches to Second-generation S1P Receptor Agonists	424
14.3.1	Overview of Second-generation Agonists	424
14.3.2	Direct Agonists – Triaryl Scaffold	424
14.3.3	Direct Agonists – Additional Chemotypes	430
14.3.4	Prodrug Agonists	435
14.4	S1P Receptor Antagonists	438
14.5	Conclusion and Clinical Landscape	439
	References	440

Chapter 15 Tipping the Balance of Sphingosine 1-Phosphate Production: Sphingosine Kinases and Sphingosine 1-Phosphate Lyase as Immune Therapeutic Targets 444

Tamas Oravecz and David Augeri

15.1	Introduction	444
15.2	Sphingosine 1-Phosphate Homeostasis	446

15.3	The Sphingosine 1-Phosphate Network and Immune Regulation	447
15.3.1	The Pro-inflammatory Function of the Sphingosine 1-Phosphate Pathway	448
15.3.2	The Anti-inflammatory Function of the Sphingosine 1-Phosphate Pathway	452
15.4	Medicinal Chemistry Approaches to Inhibit Sphingosine 1-Phosphate Lyase	455
15.4.1	Pharmaceutical Targeting of Sphingosine 1-Phosphate Lyase in Animal Models of Inflammation: PK-PD Relationship, Mechanism and Pharmacology	459
15.5	Medicinal Chemistry Approaches to Inhibit Sphingosine Kinases SK1 and SK2	463
15.6	Pharmaceutical Targeting of Sphingosine Kinases and Sphingosine 1-Phosphate Lyase in Animal Models of Inflammation	469
15.7	Concluding Remarks	470
	Acknowledgements	470
	References	470

Section 5: Steroid Hormone Receptors

Chapter 16 Non-steroidal Dissociated Glucocorticoid Receptor Agonists 481

Hossein Razavi and Christian Harcken

16.1	Introduction	481
16.2	Hydroxy-trifluoromethyl-phenyl-pentanoic Aryl Amides and Related Trifluoromethyl Carbinols	485
16.3	Dihydro-1 <i>H</i> -[1]benzopyrano[3,4- <i>f</i>]quinolines	491
16.4	Dihydro- and Tetrahydroquinolines	494
16.5	Fluorocortivazol-derived Scaffolds	497
16.6	<i>N</i> -Aryl Indazole Analogues	501
16.7	Additional Fused Cores	502
16.8	Sulfonamide-linked Scaffolds	505
16.9	Conclusion	507
	Acknowledgements	508
	References	508

Subject Index 517

Introduction

The discovery of new and novel anti-inflammatory drugs is an area of intense interest within both the pharmaceutical industry and academic laboratories. Significant advances have been made in the treatment of inflammatory diseases such as rheumatoid arthritis (RA) and multiple sclerosis, but most dramatically with new biologic agents. Perhaps due in part to the mixed experiences with COX-2 inhibitors, very few small molecule anti-inflammatory drugs with novel modes of action have made it to the market in the last decade. Therefore, there remains an enormous unmet medical need for new, effective and safe small molecule disease-modifying therapies to expand treatment options for these and other indications, including asthma and chronic obstructive pulmonary disease (COPD), allergic diseases, atherosclerosis, psoriasis, inflammatory bowel disease and pain.

Inflammatory diseases are characterized by numerous symptoms and, on a mechanistic basis, multiple pathways are involved. This multi-factorial nature of inflammation is both an opportunity and a challenge for drug discovery. The aim of this book is to review recent noteworthy medicinal chemistry approaches to a variety of important therapeutic targets and so provide a key reference for those interested in the prosecution of modern drug-discovery programs directed at anti-inflammatory mechanisms of action. The biology, pharmacology and medicinal chemistry literature of a collection of topics ranging from components of the arachidonic acid cascade, to kinases, GPCRs, sphingolipids and steroid hormone receptors have been summarized by highly respected scientists from academia and industry offering new insights on major advances and issues related to bringing new anti-inflammatory therapies to market.

In the first section of this text, drug targets in the arachidonic acid (AA) cascade are described. This pathway, although it is the molecular target of very old drugs like aspirin, is still not fully understood. For example, COX-1b ("COX-3") might be the molecular target for paracetamol (acetaminophen) in

dogs, but not in man. Taking into account the lessons of COX-2 drug development, an important downstream target is the microsomal prostaglandin E₂ synthase-1 (mPGES1), and inhibition of this mechanism has the potential to yield a third generation of non-steroidal anti-inflammatory drugs (NSAIDs).

The opposite approach, going upstream, leads to cytosolic phospholipase A₂ alpha (cPLA₂α) as a target for therapeutic intervention. The rate-limiting step in the generation of prostaglandins, leukotrienes and platelet activating factor (PAF), all highly active substances with diverse biological actions in inflammation, is the cleavage of the *sn*-2-ester of membrane phospholipids by a phospholipase A₂ (PLA₂). Among the superfamily of PLA₂ enzymes, cPLA₂α is thought to play the primary role in this biochemical reaction. Therefore, the inhibition of cPLA₂α activity is an attractive approach for the control of inflammatory disorders. Furthermore, on the leukotriene branch of the arachidonic acid cascade is the cytosolic enzyme leukotriene A₄ hydrolase (LTA₄H), which catalyzes the formation of the pro-inflammatory mediator LTB₄. The inhibition of LTA₄H offers an alternative to blocking the targets 5-lipoxygenase (5-LO) and 5-lipoxygenase activating protein (FLAP) for modulating LTB₄ levels and has potential utility for treating a variety of inflammatory disorders including coronary artery disease, though this awaits clinical validation.

The AA cascade section concludes with CRTH2, the chemoattractant receptor homologous molecule expressed on T helper type 2 cells, though this target could have also been placed in Section 3 since it is a G-protein coupled receptor (GPCR). Small-molecule antagonists of CRTH2, the receptor for prostaglandin D₂ (PGD₂), have been the subject of extensive research in the pharmaceutical industry and more than ten of these have been advanced to clinical trials for indications ranging from seasonal allergic rhinitis to asthma and atopic dermatitis, making it a very promising therapeutic target.

The second section of this volume focuses on protein kinase inhibitors as anti-inflammatory agents, although this field still suffers from important unanswered questions. From 518 protein kinases in our genome, about 250 are disease related. However, the fundamental role of kinases in signal transduction raises questions about how safe and free of side-effects kinase inhibitors can be. Another important question concerns selectivity within the human kinome. Thus, how selective is selective enough, and is the dogma “one mechanism, one target, one disease” still valid? The inhibition of multiple kinases might be beneficial in cancer, but it remains to be demonstrated that similarly promiscuous inhibitors provide the necessary safety margin for utility in treating inflammation. Despite excellent pre-clinical evidence, many kinase targets still suffer from a lack of clinically proven target validation.

Nevertheless, there has been an explosion of academic and industrial research in this field, fuelled by the groundbreaking success of anti-TNF biologicals for the treatment of rheumatoid arthritis. In the search for small-molecule drugs that impact the biosynthesis and/or release of pro-inflammatory cytokines, prominent targets include the kinases p38, MK2, Syk, JAK, IKKβ and Btk. Many p38 MAP kinase inhibitors have entered clinical trials but,